Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05507892 · ClinicalTrials.gov registry record · Phase 2
Renal Mechanism of SGLT2 Inhibition
A Phase 2 study of Type 2 Diabetes and Diabetic Kidney Disease, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT05507892 is a Phase 2 study of Type 2 Diabetes and Diabetic Kidney Disease that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 40 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05507892, a Phase 2 study of Type 2 Diabetes and Diabetic Kidney Disease, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
Canagliflozin is an oral drug which is currently approved for use in patients with type 2 diabetes by the US Food and Drug Administration (FDA). Canagliflozin acts by increasing salt and sugar loss in the urine, and has shown to protect heart, kidney, and blood vessel function in patients with type 2 diabetes. However, it is unknown how canagliflozin protects the kidneys from disease. Therefore, this study plans to learn more about how canagliflozin works to protect against diabetic kidney disease in adults with type 2 diabetes. This study will use state-of-the-art kidney imaging, kidney biopsies and detailed testing of kidney function to determine the mechanisms of protection afforded by canagliflozin.
Conditions Studied
Interventions
- DRUG canagliflozin
- DRUG Aminohippurate Sodium Inj 20%
Study Locations (2)
Colorado
- University of Colorado Denver - Aurora
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-10-10 |
| Est. Completion | 2026-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05507892
The ClinicalTrials.gov registry entry for NCT05507892 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (96% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which canagliflozin is the first listed.
NCT05507892 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Colorado, Michigan.
Frequently Asked Questions
What is clinical trial NCT05507892 about?
NCT05507892 is a clinical study titled "Renal Mechanism of SGLT2 Inhibition". Canagliflozin is an oral drug which is currently approved for use in patients with type 2 diabetes by the US Food and Drug Administration (FDA). Canagliflozin acts by increasing salt and sugar loss in the urine, and has shown to protect heart, kidney, and blood vessel function in patients with type ...
What is the current status of trial NCT05507892?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2022-10-10. Estimated completion is 2026-12-15.
What conditions does trial NCT05507892 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Diabetic Kidney Disease.
What interventions are being tested in trial NCT05507892?
The interventions under investigation include: canagliflozin (DRUG), Aminohippurate Sodium Inj 20% (DRUG).
Who is sponsoring clinical trial NCT05507892?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05507892 being conducted?
This trial has 2 study locations across Colorado, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
RECRUITING · Phase 2
-
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
RECRUITING · Phase 2
-
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
RECRUITING · Phase 2
-
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
ACTIVE NOT RECRUITING · Phase 2
-
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.